Mantle Cell Lymphoma

Interim GLOVe trial results show that the frontline combination of glofitamab, lenalidomide, and venetoclax induces rapid, deep, and predominantly MRD-negative remissions in high-risk mantle cell lymphoma with manageable toxicity.

A chemotherapy-free, MRD-guided regimen achieved deep, durable remissions in untreated MCL with manageable toxicity and the potential for time-limited therapy.

FDA has granted sonrotoclax priority review for relapsed mantle cell lymphoma, showcasing promising trial results.

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.